BeNeLuxBelgiumNetherlandsLuxembourg

Wyeth closes 165 million Euros deal

21.11.2006

Brussels – Just before the commencement of clinical trials, Ablynx, a Belgian biotech company which is developing a new class of drugs based on DNA, has closed a deal worth up a165 million with the US vaccines specialist Wyeth. The agreement allows Wyeth to develop a new generation of anti-TNF treatments for diseases such as rheumatoid arthritis using ultra-small nanobodies. Ablynx has granted exclusive worldwide rights for the use of the technology to target tumor necrosis factor alpha (TNFa), a protein implicated in inflammation, which is inhibited by existing injectable drugs such Wyeth’s Enbrel. Backed by this important pharma deal, Ablynx hopes to go public next year.

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Mechelen - Galapagos NV confirms its status as one of Europe best drug discovery companies. The Belgian biotech received €4 million as the first milestone payments from French Servier for the discovery of new targets for...

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/wyeth-closes-165-million-euros-deal.html

Video

All videos

Product of the week

Products

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Stock list

All quotes

TOP

  • CYTOS0.36 CHF5.88%
  • MERCK KGAA94.27 EUR2.25%
  • STRATEC BIOMEDICAL46.09 EUR1.97%

FLOP

  • VITA 345.55 EUR-3.48%
  • EVOTEC3.75 EUR-2.60%
  • MOLOGEN5.26 EUR-2.59%

TOP

  • WILEX3.15 EUR46.5%
  • EVOLVA1.67 CHF16.8%
  • BB BIOTECH270.05 EUR16.6%

FLOP

  • MOLOGEN5.26 EUR-12.3%
  • SANTHERA96.30 CHF-12.1%
  • 4SC0.78 EUR-8.2%

TOP

  • SANTHERA96.30 CHF2362.9%
  • WILEX3.15 EUR392.2%
  • FORMYCON16.23 EUR110.8%

FLOP

  • CYTOS0.36 CHF-87.3%
  • MOLOGEN5.26 EUR-55.9%
  • PAION2.12 EUR-52.0%

No liability assumed, Date: 03.03.2015

Current issue

All issues